1. Home
  2. RARE vs EFSC Comparison

RARE vs EFSC Comparison

Compare RARE & EFSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

HOLD

Current Price

$22.28

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Enterprise Financial Services Corporation

EFSC

Enterprise Financial Services Corporation

HOLD

Current Price

$54.69

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RARE
EFSC
Founded
2010
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
RARE
EFSC
Price
$22.28
$54.69
Analyst Decision
Strong Buy
Buy
Analyst Count
19
3
Target Price
$59.32
$66.00
AVG Volume (30 Days)
2.0M
241.4K
Earning Date
05-05-2026
04-27-2026
Dividend Yield
N/A
2.41%
EPS Growth
7.31
N/A
EPS
N/A
N/A
Revenue
$673,000,000.00
N/A
Revenue This Year
$13.12
$14.91
Revenue Next Year
$42.13
$3.60
P/E Ratio
N/A
$11.50
Revenue Growth
20.13
N/A
52 Week Low
$18.29
$45.22
52 Week High
$40.17
$62.20

Technical Indicators

Market Signals
Indicator
RARE
EFSC
Relative Strength Index (RSI) 56.66 48.97
Support Level $22.00 $53.43
Resistance Level $23.44 $58.64
Average True Range (ATR) 0.95 1.08
MACD 0.28 0.27
Stochastic Oscillator 99.76 82.54

Price Performance

Historical Comparison
RARE
EFSC

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

About EFSC Enterprise Financial Services Corporation

Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.

Share on Social Networks: